Summary
Santen Pharmaceutical Co., Ltd. (Santen) is a pharmaceutical company. It focuses on the development and manufacture of pharmaceutical products and medical devices. Santen specializes in ophthalmological products. Its product portfolio includes prescription ophthalmic products, anti-rheumatics, OTC drugs, anti-allergy ophthalmic products, prescription anti-rheumatic drugs and medical devices such as intraocular lenses, among others. The company markets its products under brand names such as Livostin, Alesion, Metadate, Cravit, Diquas and Hyalein, among others. It has manufacturing plants and laboratories in France, Japan, China, Finland and the US. The company markets its products in over 50 countries. Santen is headquartered in Osaka, Japan.
The company aims to evolve into a specialized pharmaceutical company with global presence by 2020. To this end, the company intends to accelerate the development of its pipeline candidates to realize enhanced productivity; and strengthen its market presence by entering new markets.
Santen Pharmaceutical Co., Ltd. (4536) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Santen Pharmaceutical Co., Ltd., Medical Devices Deals, 2010 to YTD 2016 10
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck for USD50 Million 14
Santen Pharma Acquires Global Rights To Sirolimus From MacuSight 16
Venture Financing 17
RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 17
InnFocus Raises USD32.8 Million in Series C Financing Round 18
Clearside Biomedical Raises USD16 Million in Series B Venture Financing 19
Clearside Biomedical Raises US$8 Million In Venture Financing 21
Partnerships 23
Durect Enters into Licensing Agreement with Santen Pharma 23
Santen Expands Research Agreement with Clearside Biomedical 24
Santen Pharma Enters into Co-Development Agreement with SERI 25
Tracon Pharma Enters Into Co-Development Agreement With Santen Pharma 26
Santen Enters Into Research Agreement With Clearside Biomedical 28
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 29
Novagali Pharma Enters Into Distribution Agreement With Ardeo Health For Nova23041 31
Novagali Pharma Enters Into Co-Promotion Agreement With OCuSOFT For Nova23041 32
Inspire Enters Into Co-Marketing Agreement With Santen 33
Banyu Pharma Enters Into Co-Promotion Agreement With Santen Pharma 34
Licensing Agreements 35
Parion Sciences Enters into Licensing Agreement with Santen Pharma For P-321 35
Santen Extends Licensing Agreement with Eupharmed to Distribute Cationorm 36
Santen Pharma Enters into Licensing Agreement with Oak Pharma 37
Santen Pharma And Eisai Enter Into Option Agreement For Ophthalmic Drugs 38
Santen Enters into Licensing Agreement with Eupharmed For Cationorm 39
Inspire Pharma Amends Licensing Agreement With Santen Pharma 40
Clinical Data Enters Into Licensing Agreement With Santen Pharma 41
Equity Offering 43
Novagali Completes IPO Of US$30 Million 43
Asset Transactions 44
Santen Pharma to Sell Anti-Rheumatic Pharma Business to Hyperion Pharma for USD375 Million 44
R-Tech Ueno Acquires Rights to DE-105 from Santen Pharma 46
Akorn Acquires Betimol, Opthalmic Drug, From Santen 47
Acquisition 48
Santen Pharma Completes Tender Offer To Acquire Remaining 49.5% Stake In Novagali Pharma For US$67.2 Million 48
Santen Pharmaceutical Co., Ltd. - Key Competitors 51
Key Employees 52
Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
List of Tables
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Santen Pharmaceutical Co., Ltd., Deals By Therapy Area, 2010 to YTD 2016 9
Santen Pharmaceutical Co., Ltd., Medical Devices Deals, 2010 to YTD 2016 10
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck for USD50 Million 14
Santen Pharma Acquires Global Rights To Sirolimus From MacuSight 16
RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 17
InnFocus Raises USD32.8 Million in Series C Financing Round 18
Clearside Biomedical Raises USD16 Million in Series B Venture Financing 19
Clearside Biomedical Raises US$8 Million In Venture Financing 21
Durect Enters into Licensing Agreement with Santen Pharma 23
Santen Expands Research Agreement with Clearside Biomedical 24
Santen Pharma Enters into Co-Development Agreement with SERI 25
Tracon Pharma Enters Into Co-Development Agreement With Santen Pharma 26
Santen Enters Into Research Agreement With Clearside Biomedical 28
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 29
Novagali Pharma Enters Into Distribution Agreement With Ardeo Health For Nova23041 31
Novagali Pharma Enters Into Co-Promotion Agreement With OCuSOFT For Nova23041 32
Inspire Enters Into Co-Marketing Agreement With Santen 33
Banyu Pharma Enters Into Co-Promotion Agreement With Santen Pharma 34
Parion Sciences Enters into Licensing Agreement with Santen Pharma For P-321 35
Santen Extends Licensing Agreement with Eupharmed to Distribute Cationorm 36
Santen Pharma Enters into Licensing Agreement with Oak Pharma 37
Santen Pharma And Eisai Enter Into Option Agreement For Ophthalmic Drugs 38
Santen Enters into Licensing Agreement with Eupharmed For Cationorm 39
Inspire Pharma Amends Licensing Agreement With Santen Pharma 40
Clinical Data Enters Into Licensing Agreement With Santen Pharma 41
Novagali Completes IPO Of US$30 Million 43
Santen Pharma to Sell Anti-Rheumatic Pharma Business to Hyperion Pharma for USD375 Million 44
R-Tech Ueno Acquires Rights to DE-105 from Santen Pharma 46
Akorn Acquires Betimol, Opthalmic Drug, From Santen 47
Santen Pharma Completes Tender Offer To Acquire Remaining 49.5% Stake In Novagali Pharma For US$67.2 Million 48
Santen Pharmaceutical Co., Ltd., Key Competitors 51
Santen Pharmaceutical Co., Ltd., Key Employees 52
Santen Pharmaceutical Co., Ltd., Other Locations 54
Santen Pharmaceutical Co., Ltd., Subsidiaries 55
List of Figures
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Santen Pharmaceutical Co., Ltd., Medical Devices Deals, 2010 to YTD 2016 10
